A win ratio approach for comparing crossing survival curves in clinical trials
暂无分享,去创建一个
Duolao Wang | J. Qiu | Tao Chen | M. Gamalo | Sirui Zheng
[1] Kyungeun Kim,et al. On recurrent-event win ratio , 2022, Statistical methods in medical research.
[2] J. Ganju,et al. Sample size formula for a win ratio endpoint , 2022, Statistics in medicine.
[3] E. Leifer,et al. Event‐specific win ratios for inference with terminal and non‐terminal events , 2021, Statistics in medicine.
[4] KyungMann Kim,et al. Sample size formula for general win ratio analysis , 2021, Biometrics.
[5] D. Hoaglin,et al. Adjusting win statistics for dependent censoring , 2020, Pharmaceutical statistics.
[6] S. Pocock,et al. Prioritized Endpoints for Device-Based Hypertension Trials: the Win Ratio Methodology. , 2020, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[7] S. Pocock,et al. The win ratio approach for composite endpoints: practical guidance based on previous experience. , 2020, European heart journal.
[8] Martin Posch,et al. Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyze RCTs in oncology , 2020, Pharmaceutical statistics.
[9] D. Hoaglin,et al. The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring , 2020, Journal of Biopharmaceutical Statistics.
[10] S. Solomon,et al. Use of the Win Ratio in Cardiovascular Trials. , 2020, JACC. Heart failure.
[11] G. Molenberghs,et al. Defining Efficacy Estimands in Clinical Trials: Examples Illustrating ICH E9(R1) Guidelines , 2020, Therapeutic Innovation & Regulatory Science.
[12] D. Hoaglin,et al. The Win Ratio: On Interpretation and Handling of Ties , 2019, Statistics in Biopharmaceutical Research.
[13] G. Koch,et al. Adjusted win ratio with stratification: Calculation methods and interpretation , 2019, Statistical methods in medical research.
[14] L. Sharples,et al. Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials: JACC Review Topic of the Week. , 2019, Journal of the American College of Cardiology.
[15] G. Molenberghs,et al. Defining Efficacy Estimands in Clinical Trials: Examples Illustrating ICH E9(R1) Guidelines. , 2019, Therapeutic innovation & regulatory science.
[16] Xun Chen,et al. Design and monitoring of survival trials in complex scenarios , 2018, Statistics in medicine.
[17] Sanjiv J. Shah,et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy , 2018, The New England journal of medicine.
[18] L. Mao,et al. On the alternative hypotheses for the win ratio , 2018, Biometrics.
[19] G. Knoll,et al. The win ratio approach did not alter study conclusions and may mitigate concerns regarding unequal composite end points in kidney transplant trials. , 2018, Journal of clinical epidemiology.
[20] Duolao Wang,et al. The stratified win ratio , 2018, Journal of biopharmaceutical statistics.
[21] Xiaodong Luo,et al. WWR: An R package for analyzing prioritized outcomes , 2017 .
[22] L. F. León,et al. Estimation of treatment effects in weighted log-rank tests , 2017, Contemporary clinical trials communications.
[23] Xiaodong Luo,et al. Weighted win loss approach for analyzing prioritized outcomes , 2017, Statistics in medicine.
[24] M. Vandemeulebroecke,et al. A generalized analytic solution to the win ratio to analyze a composite endpoint considering the clinical importance order among components , 2016, Pharmaceutical statistics.
[25] P. Parfrey,et al. The win ratio approach to analyzing composite outcomes: An application to the EVOLVE trial. , 2016, Contemporary clinical trials.
[26] W. Tsai,et al. An alternative approach to confidence interval estimation for the win ratio statistic , 2015, Biometrics.
[27] Huilin Chen,et al. Statistical Inference Methods for Two Crossing Survival Curves: A Comparison of Methods , 2015, PloS one.
[28] Zhenyu Jia,et al. Weighted Lin-Wang Tests for Crossing Hazards , 2014, Comput. Math. Methods Medicine.
[29] S. Pocock,et al. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities , 2011, European heart journal.
[30] L. Billingham,et al. Crossing survival curves: alternatives to the log-rank test , 2011, Trials.
[31] M. Buyse. Generalized pairwise comparisons of prioritized outcomes in the two‐sample problem , 2010, Statistics in medicine.
[32] David Kraus. Adaptive Neyman's smooth tests of homogeneity of two samples of survival data , 2009 .
[33] Peihua Qiu,et al. A two‐stage procedure for comparing hazard rate functions , 2007 .
[34] Peihua Qiu,et al. Comparing two crossing hazard rates by Cox proportional hazards modelling , 2007, Statistics in medicine.
[35] Jun Yan. Survival Analysis: Techniques for Censored and Truncated Data , 2004 .
[36] Mikhail Nikulin,et al. Analysis of survival data with cross-effects of survival functions. , 2004, Biostatistics.
[37] A. Khasnis,et al. Effects of Candesartan on Mortality and Morbidity in Patients With Chronic Heart Failure: The CHARM-Overall Programme , 2004 .
[38] M. Pfeffer,et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.
[39] J. Klein,et al. Survival Analysis: Techniques for Censored and Truncated Data , 1997 .
[40] D. Stablein,et al. A two-sample test sensitive to crossing hazards in uncensored and singly censored data. , 1985, Biometrics.
[41] J. Lachin,et al. Large sample inference for a win ratio analysis of a composite outcome based on prioritized components. , 2016, Biostatistics.
[42] Jaymie Shanahan,et al. A New Method For the Comparison Of Survival Distributions , 2013 .
[43] Qiang Xu,et al. A new method for the comparison of survival distributions , 2010, Pharmaceutical statistics.
[44] Fushing Hsieh,et al. On heteroscedastic hazards regression models: theory and application , 2001 .
[45] M. Pagano,et al. Survival analysis. , 1996, Nutrition.